New Drug Beats Standard Treatment in Kidney Disease Trial, Journal Reports

The New England Journal of Medicine posted results from the phase 3 MAJESTY trial, which tested two different drugs in patients with primary membranous nephropathy — a condition where the immune system damages the tiny filters inside the kidneys, causing protein to leak into the urine. The trial ran for 104 weeks and compared obinutuzumab, a type of antibody treatment that targets immune cells, against tacrolimus, a drug that suppresses the immune system and is currently used as a standard option for this condition.

Obinutuzumab produced higher rates of complete remission (where protein loss returns to near-normal levels) than tacrolimus over the course of the trial, according to the journal’s summary of findings.

Primary membranous nephropathy is one of the more common causes of a kidney condition called nephrotic syndrome in adults. Without effective treatment, it can progress to kidney failure in a significant proportion of patients.

Tacrolimus belongs to a class of drugs called calcineurin inhibitors. Obinutuzumab works differently — it is classed as a type II anti-CD20 antibody, meaning it targets and depletes a specific type of white blood cell thought to drive the immune attack on the kidneys. The distinction matters clinically, as the two approaches carry different side-effect profiles and relapse risks.

The MAJESTY trial results are phase 3 data, which is the stage of clinical research that directly compares a new treatment against an existing one in a large patient group before regulators consider approval. Whether obinutuzumab will become a routine treatment option in the UK will depend on review by bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE).

Anyone concerned about kidney symptoms — including persistent swelling, foamy urine, or fatigue — should contact their GP or call NHS 111.